Foreword
Recently, Prof. Matthias Stelljes of the University of Münster, Germany, visited China for an academic exchange and shared new advances from Europe in the treatment of ALL. The transplant center at the University of Münster, where Prof. Stelljes is based, is one of the largest transplant centers in Europe; he has participated in multiple global pivotal clinical trials including INOVATE, and is the leading principal investigator (Leading PI) of the global multicenter INITIAL-1 study, with extensive experience in the treatment of acute leukemia and allogeneic stem cell transplantation. For patients with R/R B-ALL, CAR-T cell therapy has become an important immunotherapy approach. Inotuzumab, a highly efficient CD22-targeted ADC, has been explored in recent years as a bridging regimen before CAR-T; however, whether it affects T-cell expansion after CAR-T infusion and whether it can bring better treatment outcomes to R/R B-ALL patients remains a focus of attention for clinicians.
Expert Profile: Prof. Matthias Stelljes
• Head of the Hematopoietic Stem Cell Transplantation Center and the CAR-T Center, University of Münster, Germany; specialty areas: HSCT, ALL, AML
• EBMT National Representative for Germany
• JACIE (Joint Accreditation Committee of the ISCT and the EBMT) Accreditation Reviewer
• Steering Committee Member, German Working Group on Hematopoietic Stem Cell Transplantation and Cellular Therapy
• Committee Member, German ALL Study Group (GMALL)
• Expert Panel Member, German Study Alliance Leukemia (SAL)
• Expert Panel Member, AML Cooperative Group
Q1. Does inotuzumab affect T-cell expansion, and thereby affect the efficacy of CAR-T?
Prof. Matthias Stelljes:
Prof. Stelljes clearly pointed out that bridging CAR-T with inotuzumab does not affect T-cell function. However, viewed from the therapeutic target, current clinical CAR-T products mainly target CD19; patients who have received blinatumomab may experience CD19 downregulation, which can affect the efficacy of subsequent CD19-targeted CAR-T therapy. In contrast, inotuzumab targets CD22, which is different from most CAR-T targets; the complementary mechanisms produce a synergistic effect, which is conducive to more efficient clearance of tumor cells.
Q2. What is the efficacy and safety of inotuzumab as a CAR-T bridging regimen in real-world studies?
Prof. Matthias Stelljes:
CAR-T therapy in clinical practice often faces a thorny problem: some patients have an excessively high tumor burden, making it impossible to collect a sufficient number of normally functioning T lymphocytes, leading to CAR-T manufacturing failure or suboptimal efficacy. In response, multiple clinical studies have shown that inotuzumab as a bridging treatment before CAR-T can effectively reduce tumor burden, increase the MRD-negative rate, and does not affect T-cell collection or in vivo CAR-T expansion:
- l A real-world study from the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, compared the efficacy of inotuzumab and blinatumomab as bridging therapy before CAR-T. It enrolled 22 high-risk R/R B-ALL patients with poor baseline characteristics (59.1% with extramedullary disease, 36.4% BCR::ABL1-positive). In terms of efficacy, although the inotuzumab bridging group had a higher tumor burden and more extramedullary disease, the post-bridging CR/PP rate still reached 60.0%, with bone marrow blasts reduced by 85%; the CR rate after CAR-T infusion reached 73.3%, and the 1-year OS rate was 80%. Clear CAR-T expansion was detected, with a median CAR-T expansion peak on day 8 post-infusion of 53,400 copies/μg DNA, suggesting that inotuzumab does not affect the in vivo proliferation capacity of CAR-T cells.
- l A European/American multicenter real-world study enrolling 84 R/R B-ALL patients evaluated the efficacy and safety of inotuzumab as a CAR-T bridging regimen. After bridging, median bone marrow blasts dropped from 62.5% to 2.0%; 66.0% of patients had bone marrow blasts <5%, and 43.1% achieved MRD-negative status. 100% of patients successfully completed apheresis, and 84.5% successfully received CAR-T infusion. The CR/CRh/CRi rate after CAR-T infusion was 76.7%, and the 12-month OS rate was 72.5%. This study confirmed that inotuzumab bridging can significantly reduce tumor burden in patients, does not affect subsequent T-cell apheresis, and yields clear long-term survival benefit.
- l A Spanish retrospective study enrolling 24 pediatric and young adult R/R B-ALL patients compared the efficacy of inotuzumab with chemotherapy as a CAR-T bridging regimen. In the inotuzumab group, 80% of high-tumor-burden patients successfully converted to low burden (vs. 28.6% in the chemotherapy group), 60% achieved MRD-negative status (vs. 14.3% in the chemotherapy group), and the inotuzumab group had a higher proportion of CD8+ stem-cell memory T cells.
Summary
Synthesizing expert opinions and real-world data, inotuzumab bridging before CAR-T does not affect T-cell function, but rather effectively “clears the obstacles” for high-tumor-burden patients, increases the MRD-negative rate, and improves the pre-infusion disease status, thereby creating better conditions for CAR-T therapy, with subsequent CAR-T treatment achieving high remission and survival rates. Therefore, for patients with high tumor burden and no effective bridging regimen, an inotuzumab bridging regimen is a treatment strategy worth prioritizing.
References
[1] 2025 ASH. Abstract P2324
[2] 2025 ASH. Abstract P2369
[3] 2025 ASH. Abstract P2398